Delivering gene therapy pricing strategy where payer interviews had failed: The power of Behavior-Based Pricing

Our client had a novel “one and done” gene therapy for an ultra-orphan disease. Despite previous payer research, the client lacked direction in which patient segments to target, what list to net pricing strategy to take, and what net price they could achieve. They needed an efficient and quantitative solution to inform their key development decisions.

Back to Case Studies

The “one and done” gene therapy made payers uncertain

Because of the one-time administration, payers were uncertain around the longevity of the benefit that would be provided outside of the payment year. Our client was eager to quantify how this uncertainty would affect their price potential – and knew they needed more than payer interviews to understand this.

Multiple patient segment and product profile scenarios required an efficient modeling approach

Our client had multiple product profiles and patient population scenarios to consider in their price strategy. To leave no stone unturned, they needed an approach that could efficiently quantify the therapy’s price potential in each scenario and deliverables which easily communicated scenario price differences…

…read how Behavior-Based Pricing™ did just that.

Download the document by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top